Taken together, these findings provide a rationale for the combination of multiple HER2 inhibitors or inhibitors of the downstream signaling axis in patients with HER2-mutant breast cancer, a therapeutic strategy that has already proven highly effective in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.